Clinical Trial Detail

NCT ID NCT01313559
Title Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
Recruitment Terminated
Gender male
Phase Phase II
Variant Requirements no
Sponsors Thomas Jefferson University
Indications

prostate adenocarcinoma

Therapies

Everolimus + Pasireotide

Pasireotide

Age Groups: adult

No variant requirements are available.